Texas, US and Oxford, UK, 11th September 2023: Orano Med SAS, “Orano Med”, a biotechnology company developing Lead-212 (212Pb) Targeted Alpha Therapy against cancer, and Orbit Discovery Ltd, “Orbit”, a leader in the discovery of therapeutic peptide hits, today announced that they have entered into a collaboration to discover specific Peptide Receptor Radionuclide Therapies against […]
New Jersey, USA, and Oxford, UK: Evergreen Discovery (Evergreen), a leading radiopharmaceutical drug development company with a focus on the treatment and diagnosis of cancer, and Orbit Discovery Ltd (Orbit), a leader in the discovery of therapeutic peptide hits, announced today that they have entered into a collaboration to identify specific cell targeting peptides and […]
Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a multi target Research Agreement with Endevica Bio Inc., (Endevica), a company dedicated to creating first-in-class therapeutics for cachexia caused by cancer and other chronic conditions, with its lead compound having proven safe and well-tolerated in […]
Oxford, UK, 05 January 2023: Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a Master Service Agreement with SanegeneBio Inc., (Sanegene), a start-up company dedicated to developing novel RNAi-based medicines. The focus of the collaboration is to identify tissue-specific delivery of a wide range […]
We are looking forward to the upcoming JPM meeting in San Francisco. The Orbit Display Platform is ideal for high throughput biologic library screening. To date, the platform has been used to identifying hits suitable for: Protein Protein Interactions including (Protacs / molecular glues) Targeting radionucleotides and oligonucleotide therapeutics; and, High throughput functional screens to […]
Dr Jordan Palfry will be attending TIDES Europe between the 16th and 18th November. If you have an interest in peptide discovery, be it for targeting cells, PROTACS and molecular Glues or for functional screening in identifying GPCR agonists, please connect via info@orbitdiscovery.com. We look forward to meeting you in Boulder
Neil Butt (CEO) of Orbit Discovery will be attending the Peptide Symposium in Boulder Col0rado (7th – 10th November) . If you have an interest in peptide and/or small scaffold discovery, be it for targeting cells, PROTACS and Molecular Glues or for functional screening in identifying GPCR agonists, please connect via info@orbitdiscovery.com. We look forward […]
Project will use microfluidic technology to improve efficiency of peptide therapeutics discovery for challenging drug target Oxford, United Kingdom, 13th June, 2022: Orbit Discovery Ltd., (“Orbit”) a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has been awarded a Smart grant by Innovate UK, the […]